![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Mannkind Corporation |
---|---|
Information provided by: | Mannkind Corporation |
ClinicalTrials.gov Identifier: | NCT00423254 |
The majority of tumors are ignored by the immune system and it was thought for long time that tumor antigens did not exist. However, recently a number of tumor antigens have been described. These antigens reside on cancer cells and can be recognized by specific T-cells which can ultimately attack and destroy the tumor. The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
Condition | Intervention | Phase |
---|---|---|
Advanced Cancer |
Biological: MKC1106-PP |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1, Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advanced Solid Malignancies |
Estimated Enrollment: | 24 |
Study Start Date: | February 2007 |
The multi-component active immunotherapy, MKC1106-PP, consists of 1 plasmid dose and 2 peptides doses of sterile aqueous solutions designed to stimulate an immune reaction to two tumor associated antigens (PRAME and PSMA). A prime-boost treatment strategy will be employed wherein the plasmid component will be administered on Days 1, 4, 15 and 18 of each treatment cycle followed by administration of peptides on Days 29 and 32 of the treatment cycle. All components will be administered separately into superficial inguinal lymph nodes under ultrasound guidance . Subjects will undergo immunologic evaluation on Day 39 of each treatment cycle, and will undergo an evaluation for extent of disease following every other treatment cycle. Subjects who do not have evidence of progressive neoplasia may remain in the clinical trial and receive up to 6 cycles of clinical trial treatment.
Two cohorts of subjects will be treated:
both cohorts will receive the same dose of plasmid.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Arizona Cancer Center | Recruiting |
Tucson, Arizona, United States, 85724 | |
Contact: Ruth Canamar, BA 520-626-6515 | |
Principal Investigator: Lee Cranmer, MD | |
United States, California | |
University of Southern California, Norris Cancer Center | Terminated |
Los Angeles, California, United States, 90033 | |
United States, District of Columbia | |
Lombardi Comprehensive Cancer Center at Georgetown University | Recruiting |
Washington, District of Columbia, United States, 20057 | |
Contact: Ion Coarla, MD, PhD 202-687-4510 | |
Principal Investigator: John Marshall, MD | |
United States, Florida | |
H. Lee Moffitt Cancer Center and Research Institute | Recruiting |
Tampa, Florida, United States, 33612 | |
Contact: Patricia Urbas, RN,OCN 813-745-8352 | |
Principal Investigator: Jeffrey Weber, M.D., Ph.D. | |
United States, Nevada | |
Nevada Cancer Institute | Recruiting |
Las Vegas, Nevada, United States, 89135 | |
Contact: Sandra C. Lahr, RN, MSN 702-822-5174 slahr@nvcancer.org | |
Principal Investigator: Nicholas J. Vogelzang, M.D. | |
United States, New Hampshire | |
Dartmouth Hitchcock Medical Center | Recruiting |
Lebanon, New Hampshire, United States, 03756-0001 | |
Contact: Julia Yureneva, M.D. 6036504849 Julia.Yureneva@Hitchcock.org | |
Contact: Kate Mackay, RN, BSN 6036505028 Kathleen.mackay@hitchcock.org | |
Principal Investigator: Marc S. Ernstoff, M.D., F.A.C.P |
Study ID Numbers: | MKC1106-PP-001 |
Study First Received: | January 12, 2007 |
Last Updated: | May 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00423254 |
Health Authority: | United States: Food and Drug Administration |
Neoplasms |